keratin associated protein 5-7Genealiases: KRTAP5-3 · KRTAP5.7
Q-omics provides the consensus-scored KRTAP5-7 profile across patient tissues and cancer cell-line models. KRTAP5-7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KRTAP5-7 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, KRTAP5-7 RNA expression shows 12,791 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where KRTAP5-7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP5-7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP5-7 survival associations across molecular data types. KRTAP5-7 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP5-7 RNA expression–survival associations across cancer types. High KRTAP5-7 expression shows unfavorable associations in UCEC, SKCM, PRAD and KIRP, but favorable associations in HNSC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KRTAP5-7 RNA expression.
This table summarizes KRTAP5-7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP5-7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP5-7 shows lower tumor expression in READ and KIRP and higher tumor expression in KICH, BRCA, LIHC and STAD. The KICH box plot shows higher KRTAP5-7 RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with KRTAP5-7 in patient tissues and cancer cell lines. In patient samples, KRTAP5-7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP5-7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
